Can a pill keep blood cancer away after transplant?
NCT ID NCT04980404
First seen Apr 04, 2026 · Last updated Jun 19, 2026 · Updated 14 times
Summary
This phase 1 trial tests whether the oral drug Inqovi (decitabine/cedazuridine) can help prevent myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) from returning after a stem cell transplant. About 22 adults who have had a reduced-intensity transplant will take Inqovi as maintenance therapy. The main goal is to find the safest and most tolerable dose schedule.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Inqovi (decitabine and cedazuridine combination tablet)
What this could lead to
If it works, this could point toward a way to keep MDS or CMML from coming back after a stem cell transplant.
What could go wrong
This is a very early phase 1 trial with only 22 people, so it is mainly checking safety and dosing. It may not show a clear benefit, and side effects like graft-versus-host disease are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.